Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR trial of intestinal ESBL-E eradication in high-risk immunocompromised patients
2013-003048-21Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Sep 2013
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of fosfomycin, colistin and gentamicin in Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae (2 arms), sponsored by University of Cologne. Primary endpoint: Short-term intestinal eradication. Started Sep 2013; status: terminated.
02
Drugs
fosfomycincolistingentamicin
03
Conditions
Intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae
Beyond the preview
Go deeper on 2013-003048-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003048-21.